Allergan Has Tentative Agreement to End Restasis Antitrust Case

Antitrust litigation over an alleged scheme by AbbVie Inc. subsidiary Allergan to delay generic versions of the dry-eye treatment Restasis was put on hold by a federal judge in Brooklyn while the company finalizes a settlement in principle that would bring the dispute to an end.

Judge Nina Gershon paused the case Wednesday so the two sides can hammer out a formal deal resolving class action claims on behalf of “end payers” like insurers and pension funds that are leading part of the lawsuit in the U.S. District Court for the Eastern District of New York.

The tentative settlement comes ...